<DOC>
	<DOCNO>NCT02749032</DOCNO>
	<brief_summary>The present study phase I , single-centre , double-blind , randomize , cross-over ( 3 treatment , 3 treatment period 6 sequence ) , stratify ( background medication : metformin vs. diet-only ) , placebo-controlled study , compare period last 6-9 day treatment repeat dos vildagliptin , sitagliptin , placebo , wash-out period treatment period last 21 day minimum . The study design directly compare effect vildagliptin sitagliptin incretin hormone response , glycaemia , insulin well glucagon secretory response patient type 2 diabetes .</brief_summary>
	<brief_title>Feed-Back Suppression Meal-Induced Glucagon-like Peptide 1 ( GLP-1 ) Secretion</brief_title>
	<detailed_description>Design . The present study phase I , single-centre , double-blind , randomize , cross-over ( 3 treatment , 3 treatment period 6 sequence ) , stratify ( background medication : metformin vs. diet-only ) , placebo-controlled study , compare period last 6-9 day treatment repeat dos vildagliptin , sitagliptin , placebo , wash-out period treatment period last 21 day minimum . Experimental procedure . Meal test perform morning overnight fast . The standardized mixed meal compose 2 egg ( 100 g ) , 1 slice ( 50 g ) whole grain rye bread , 1 slice ( 50 g ) rye flour bread , 10 g fat-reduced margarine , 20 g boil ham , 25 g diet jam , amount 450 kcal , 50 % carbohydrate , 20 % protein , 30 % fat ( base calorie count ) . Patients allow drink tea ( black fruit-based ) de-caffeinated coffee ad libitum . Blood sample . Plasma glucose determine capillary sample take hyperaemic ear lobe . Venous blood collect indwell venous cannula place distal forearm vein , determination insulin , C-peptide , glucagon , GLP-1 ( total ) , GLP-1 ( intact ) , glucose-dependent insulinotropic polypeptide ( GIP ) ( total ) , GIP ( intact ) , free fatty acid . After draw basal blood specimen -15 0 min , blood take 15 , 30 , 45 , 60 , 90 , 120 , 180 , 240 min . Laboratory determination . Glucose , insulin , C-peptide , total GLP-1 ( C-terminally direct assay ) , intact GLP-1 ( sandwich ELISA ) , total GIP ( C-terminally direct assay ) , intact GIP ( N-terminally direct assay ) glucagon determine .</detailed_description>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>diabetes mellitus type 2 one year , define American Diabetes Association bodymassindex 20.0 40.0 kg/m² ( inclusive ) , glycohaemoglobin ( HbA1c ) ≤ 8.5 % , normal vital sign 10 minute rest supine position : systolic blood pressure 96 mmHg 159 mmHg ; diastolic blood pressure 46 mmHg99 mmHg ; heart rate 4699 bpm laboratory parameter within normal range , abnormality judge clinically irrelevant investigator ( serum estimate glomerular filtration rate enforce &gt; 60 ml/min ; hepatic enzyme bilirubin ( unless subject document Gilbert syndrome ) &gt; 3fold upper limit normal ) woman childbearing potential ( less two year postmenopausal surgically sterile 3 month ) , prove negative serum βhuman chorionic gonadotropin ( HCG ) pregnancy test screen negative urine βHCG pregnancy test day 1 treatment period , use highly effective method birth control ( failure rate le 1 % per year ) normal clinically irrelevant finding medical history physical examination glucoselowering drug therapy metformin 3 month first treatment period history presence clinically relevant cardiovascular , pulmonary , gastrointestinal , hepatic , renal , metabolic ( apart diabetes mellitus type 2 ) , haematological , neurological , psychiatric , systemic , ocular , gynaecologic , infectious disease ; acute infectious disease sign acute illness symptom clinically significant illness 3 month study , , accord investigator 's opinion , could interfere purpose study congestive heart failure New York Heart Association ( NYHA ) functional class IIIIV Regular use medication metformin last month study start exception thyroid hormone , lipidlowering antihypertensive drug , , female , exception hormonal contraception menopausal hormone replacement therapy blood loss ( &gt; 300 ml , reason ) within 3 month inclusion , haemoglobin &lt; 11.0 g/dl participation trial investigational drug past three month presence history drug allergy clinically significant allergic disease accord investigator 's judgment include know hypersensitivity DPP4 inhibitor presence drug alcohol abuse ( alcohol consumption &gt; 40 gram / day ) female , pregnancy ( define positive βHCG blood test ) , breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>